Meet Our Editorial Board Member

Detlev Boison, PhD

Legacy Research Institute
Portland, OR 97202,
USA

After receiving a doctorate in Biochemistry at the University of Köln, Germany, in 1995, Dr. Boison continued his scientific career at the Institute of Pharmacology at the University of Zürich and the Federal Institute of Technology in Zürich, Switzerland, where he began to focus on therapeutic epilepsy research and received a Habilitation in Cellular Pharmacology. In 2005 he moved to the Legacy Research Institute in Portland, Oregon, where he is currently the Robert Stone Dow Chair of Neurology and Director of Neurobiology Research (Robert Stone Dow Neurobiology Laboratories) and the Director of Basic and Translational Research of the Legacy Research Institute. He is also Adjunct Full Professor at Oregon Health and Science University (Department of Neurology) and Adjunct Full Professor at Washington State University (Department of Veterinary Medicine).

Detlev Boison

He has published 132 papers (PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/?term=Boison+D+NOT+cocoa+NOT+Gao>) with an h-index of 43 (Scopus) and delivered >100 invited lectures in >20 different countries.

REFERENCES

- [1] Huber, A., Padrun, V., Deglon, N., Aebischer, P., Mohler, H., and Boison, D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. *Proc. Natl. Acad. Sci. U.S.A.*, **2001**, 98, 7611-7616.
- [2] Li, T., Ren, G., Lusardi, T., Wilz, A., Lan, J.Q., Iwasato, T., Itoharu, S., Simon, R.P., and Boison, D. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. *J. Clin. Inv.*, **2008**, 118, 571-582.
- [3] Masino, S.A., Li, T., Theofilas, P., Sandau, U.S., Ruskin, D.N., Fredholm, B.B., Geiger, J.D., Aronica, E., and Boison, D. A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. *J. Clin. Inv.*, **2011**, 121, 2679-2683.
- [4] Shen, H.Y., Singer, P., Lytle, N., Wei, C.J., Lan, J.Q., Williams-Karnesky, R.L., Chen, J.F., Yee, B.K., and Boison, D. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. *J. Clin. Inv.*, **2012**, 122, 2567-2577.
- [5] Williams-Karnesky, R.L., Sandau, U.S., Lusardi, T.A., Lytle, N.K., Farrell, J.M., Pritchard, E.M., Kaplan, D.L., and Boison, D. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. *J. Clin. Inv.*, **2013**, 123, 3552-3563.